



Model List of Essential Medicines

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Supportive medicines Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Anastrozole

Section	Indications
Hormones and antihormones Oral > Solid: 1 mg tablet	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines Powder for injection: 10 000 IU in vial.	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Atezolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung

Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma
	Follicular lymphoma

Bicalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 50 mg	Malignant neoplasms of prostate

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15 mg in vial (as sulfate) Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines Oral > Solid: 15 mg tablet Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Solid > tablet: 15 mg; 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon

Capecitabine

Section	Indications
Cytotoxic medicines Oral > Solid: 150 mg tablet; 500 mg tablet	Malignant neoplasms of colon Other specified malignant neoplasms of breast Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum

Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis

Chlorambucil

Section	Indications
Cytotoxic medicines Oral > Solid: 2 mg tablet	Unspecified malignant neoplasms of ill-defined or unspecified sites Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cisplatin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection</p> <p>Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Malignant neoplasms of nasopharynx</p> <p>Germ cell tumour of testis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Malignant neoplasms of lip, oral cavity or pharynx</p> <p>Malignant neoplasms of cervix uteri</p>

Cladribine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial</p>	<p>Langerhans cell histiocytosis</p>

Cobimetinib

Section	Indications
<p>Targeted therapies</p>	<p>Therapeutic equivalent to trametinib for</p> <p>Other specified melanoma of skin</p>

Crizotinib

Section	Indications
<p>Targeted therapies</p> <p>Oral > Solid: 200 mg; 250 mg</p> <p>Oral > Solid > capsule: 200 mg; 250 mg</p>	<p>Other specified malignant neoplasms of bronchus or lung</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>

Cyclophosphamide

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Solid: 25 mg tablet	Burkitt lymphoma including Burkitt leukaemia
Parenteral > General injections > unspecified: 500 mg in vial powder for injection	Malignant neoplasms of breast
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection	Ewing sarcoma of bone and articular cartilage of unspecified sites
Oral > Solid: 25 mg; 50 mg	Lymphoid leukaemia, not elsewhere classified
Oral > Solid: 25 mg; 50 mg tablet	Chronic lymphocytic leukaemia or small lymphocytic lymphoma
	Diffuse large B-cell lymphomas
	Plasma cell myeloma
	Other specified gliomas of brain
	Other specified malignant neoplasms of breast
	Malignant trophoblastic neoplasms of placenta
	Follicular lymphoma
	Malignant neoplasms of kidney, except renal pelvis
	Rhabdomyosarcoma primary site
	Hodgkin lymphoma
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive

Cytarabine

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Lymphoid leukaemia, not elsewhere classified
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial	Myeloid leukaemia
	Acute myeloid leukaemia with recurrent genetic abnormalities
	Burkitt lymphoma including Burkitt leukaemia
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive
	Langerhans cell histiocytosis

Dabrafenib

Section	Indications
Targeted therapies Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dacarbazine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	Hodgkin lymphoma

Dactinomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 µg in vial powder for injection	Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites

Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Dasatinib

Section	Indications
Targeted therapies Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)</p>	<p>Lymphoid leukaemia, not elsewhere classified</p> <p>Myeloid leukaemia</p> <p>Acute myeloid leukaemia with recurrent genetic abnormalities</p>

Dexamethasone

Section	Indications
<p>Hormones and antihormones</p> <p>Oral > Solid: 4 mg</p> <p>Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)</p> <p>Oral > Liquid: 2 mg per 5 mL</p> <p>Oral > Solid: 2 mg; 4 mg</p>	<p>Plasma cell myeloma</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>

Docetaxel

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL</p>	<p>Other specified malignant neoplasms of breast</p> <p>Malignant neoplasms of breast</p> <p>Malignant neoplasms of prostate</p> <p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p>

Doxorubicin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)</p> <p>Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)</p> <p>Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Follicular lymphoma</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Malignant neoplasms of breast</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Other specified malignant neoplasms of breast</p> <p>Diffuse large B-cell lymphomas</p> <p>Plasma cell myeloma</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Hodgkin lymphoma</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>

Encorafenib

Section	Indications
Targeted therapies	<p>Therapeutic equivalent to dabrafenib for</p> <p>Other specified melanoma of skin</p>

Enzalutamide

Section	Indications
<p>Hormones and antihormones</p> <p>Oral > Solid: 40 mg</p>	<p>Therapeutic equivalent to abiraterone for</p> <p>Malignant neoplasms of prostate</p> <p>Malignant neoplasms of prostate</p>

Erlotinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Etoposide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule Oral > Solid: 100 mg capsule Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule; 50 mg capsule	Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Everolimus

Section	Indications
Targeted therapies Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)	Other specified gliomas of brain

Filgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Fludarabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule Parenteral > General injections > IV: 50 mg per mL in vial	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Fulvestrant

Section	Indications
Hormones and antihormones Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

Hydrocortisone

Section	Indications
Hormones and antihormones Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia

Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section	Indications
Targeted therapies Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Imatinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1 Gastrointestinal stromal tumour of unspecified gastrointestinal sites Chronic myeloid leukaemia, not elsewhere classified

Irinotecan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Leuprorelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Mesna

Section	Indications
<p>Supportive medicines</p> <p>Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule</p> <p>Oral > Solid: 400 mg; 600 mg</p>	<p>Osteosarcoma of bone and articular cartilage of other specified sites</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p>

Methotrexate

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial (as sodium salt)</p> <p>Oral > Solid: 2.5 mg (as sodium salt)</p> <p>Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Acute myeloid leukaemia with recurrent genetic abnormalities</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of breast</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p> <p>Langerhans cell histiocytosis</p>

Methylprednisolone

Section	Indications
<p>Hormones and antihormones</p> <p>Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)</p>	<p>Lymphoid leukaemia, not elsewhere classified</p> <p>Burkitt lymphoma including Burkitt leukaemia</p>

Nilotinib

Section	Indications
Targeted therapies Oral > Solid: 150 mg capsule; 200 mg capsule	Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Nivolumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Melanoma of skin

Oxaliplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

Pegaspargase

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pembrolizumab

Section	Indications
Immunomodulators	Therapeutic equivalent to nivolumab for Melanoma of skin

Pertuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Prednisolone

Section	Indications
Hormones and antihormones Oral > Liquid: 5 mg per mL Oral > Solid: 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Plasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis

Prednisone

Section	Indications
Hormones and antihormones	<p>Therapeutic equivalent to prednisolone for</p> <p>Plasma cell myeloma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Follicular lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Lymphoid leukaemia, not elsewhere classified</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Malignant neoplasms of prostate</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Hodgkin lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Diffuse large B-cell lymphomas</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Anaplastic large cell lymphoma, ALK-negative</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Langerhans cell histiocytosis</p>

Procarbazine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg (as hydrochloride)	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Hodgkin lymphoma</p>

Rasburicase

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution	<p>Tumour lysis syndrome</p>

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Rituximab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas

Tamoxifen

Section	Indications
Hormones and antihormones Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

Tioguanine

Section	Indications
Cytotoxic medicines Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas

Tislelizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 10 mL	Malignant neoplasms of urinary tract Hodgkin lymphoma

Trametinib

Section	Indications
Targeted therapies Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Trastuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast
	Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

Vinblastine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)</p> <p>Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Hodgkin lymphoma</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p> <p>Langerhans cell histiocytosis</p>

Vincristine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)</p> <p>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Follicular lymphoma</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Rhabdomyosarcoma primary site</p> <p>Hodgkin lymphoma</p> <p>Diffuse large B-cell lymphomas</p> <p>Retinoblastoma</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Langerhans cell histiocytosis</p>

Vinorelbine

Section	Indications
Cytotoxic medicines	Other specified malignant neoplasms of bronchus or lung
Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial	Other specified malignant neoplasms of breast
Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial	Rhabdomyosarcoma primary site
Oral > Solid: 20 mg; 30 mg; 80 mg	

Zanubrutinib

Section	Indications
Targeted therapies	Mantle cell lymphoma
Oral > Solid: 80 mg	

Zoledronic acid

Section	Indications
Supportive medicines	Malignant neoplasm metastasis in bone or bone marrow
Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	